+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Zydus Cadila - logo

Zydus Cadila Pharmaceutical is a global healthcare provider. The origins of this group go back to 1952, however in 1995 this group restructured its operations and the Cadila group were taken over by the Zydus group. It is the only Indian pharma company to launch its own patented NCE. They developed a drug for diabetic dyslipidemia, Lipaglyn. This is the first drug to be approved for this disease. They are the 4th largest in the Indian pharma market. Other than their successful sales from India, Zydus gains a wider market share through its subsidiaries in the U.S, Europe (France and Spain), South Africa and Latin America. From their beginning in 1995 to today Zydus has shown major growth rates in revenue.

From
Bevacizumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Bevacizumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
From
From
From
From
Levofloxacin Global Market Report 2023 - Product Thumbnail Image

Levofloxacin Global Market Report 2023

  • Report
  • August 2023
  • 175 Pages
  • Global
From
Ampicillin Market Analysis - Product Thumbnail Image

Ampicillin Market Analysis

  • Report
  • May 2021
  • 147 Pages
  • Global
From
Global Infliximab Drug Market Report and Forecast 2023-2031 - Product Thumbnail Image

Global Infliximab Drug Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Lifestyle Drugs - Global Strategic Business Report - Product Thumbnail Image

Lifestyle Drugs - Global Strategic Business Report

  • Report
  • November 2023
  • 184 Pages
  • Global
From
Adalimumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Adalimumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
From
From
Hydroxychloroquine Global Market Report 2023 - Product Thumbnail Image

Hydroxychloroquine Global Market Report 2023

  • Report
  • February 2023
  • 250 Pages
  • Global
From
Teriparatide- Biosimilar Insight, 2022 - Product Thumbnail Image

Teriparatide- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Polycystic ovary syndrome - Pipeline Insight, 2023 - Product Thumbnail Image

Polycystic ovary syndrome - Pipeline Insight, 2023

  • Drug Pipelines
  • July 2023
  • 60 Pages
  • Global
From
Peptic Ulcer Drugs - Global Strategic Business Report - Product Thumbnail Image

Peptic Ulcer Drugs - Global Strategic Business Report

  • Report
  • November 2023
  • 196 Pages
  • Global
From
Hepatitis Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Hepatitis Therapeutics - Global Strategic Business Report

  • Report
  • November 2023
  • 94 Pages
  • Global
From
Loading Indicator